Physician profile
Gary Duke Wolf
NPI 1619995693
$1,984.77
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $855 · 2020: $550 · 2021: $566 · 2022: $14.27.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $338.83 | 2019-2022 | |
| Novo Nordisk INC | $269.91 | 2019-2021 | |
| Allergan, INC. | $216.53 | 2019-2020 | |
| Lilly USA, LLC | $205.38 | 2019-2021 | |
| Abbvie INC. | $144.81 | 2019-2021 | |
| Glaxosmithkline, LLC. | $140.44 | 2019-2021 | |
| Pfizer INC. | $100.78 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.11 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $50.56 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $49.33 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $46.66 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $45.39 | 2019-2020 | |
| Amarin Pharma, INC. | $36.47 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $35.57 | 2019 | |
| Amgen INC. | $34.29 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $32.79 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $22.99 | 2019 | |
| Abbott Laboratories | $17.64 | 2021 | |
| Astellas Pharma US INC | $17.47 | 2021 | |
| Vertical Pharmaceuticals, LLC | $16.56 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.14 | 2021 | |
| Antares Pharma, INC. | $15.13 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $15.09 | 2021 | |
| Clarus Therapeutics INC. | $14.23 | 2021 | |
| Sanofi Pasteur INC. | $13.56 | 2019 | |
| Upsher-Smith Laboratories LLC | $12.96 | 2019 | |
| Therapeuticsmd, INC. | $11.76 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.39 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Wolf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.